CN Mobile Logo

Search form


SGO 2017

SGO Annual Meeting on Women’s Cancer

Cancer Network presents exclusive coverage from the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held March 12–15 in National Harbor, Maryland. We bring you expert interviews and bring you reports highlighting the latest trials, scientific advances, and controversies that are changing the way gynecologic cancers are managed and treated.

SGO 2017

Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies.

The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.

A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.

In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.

Treating women with stage IVB cervical cancer with whole pelvic radiation along with standard chemotherapy improved survival over chemotherapy alone in a retrospective study.

The use of sentinel lymph node biopsy alone in women with early cervical cancer resulted in less surgical morbidity without a significant increase in the risk of recurrence, according to a new prospective study.


Subscribe to SGO 2017 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.